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Abstract: The endoscopic treatment of cancerous and pre-
cancerous lesions in the gastrointestinal (GI) tract has expe-
rienced major breakthroughs in the past years. Endoscopic 
mucosal resection (EMR) is a simple and efficient method 
for the treatment of most benign lesions in the GI tract. 
However, with the introduction of endoscopic submucosal 
dissection (ESD) and endoscopic full-thickness resection 
(EFTR), the scope of lesions eligible for endoscopic treat-
ment has been widened significantly even in the colon. 
These methods are now being used routinely not just for the 
treatment of benign lesions but also in the curative en bloc 
resection of early colorectal cancers. The quick, efficient, 
and noninvasive character of these endoscopic procedures 
make them not just an alternative to surgery but, in many 
cases, the methods of choice for the treatment of most early 
colon cancers and some rectal cancers.
Keywords: early colorectal cancer; EMR; ESD; full-thick-
ness resection; TEMS.
Introduction
The endoscopic treatment of precancerous and early can-
cerous lesions in the gastrointestinal (GI) tract has experi-
enced major breakthroughs in the last decades especially 
with the introduction of resection methods such as endo-
scopic submucosal dissection (ESD) and the full-thickness 
resection device (FTRD) technique. In any comparison 
between endoscopic treatment and surgery, the advantages 
of the former, including lower cost and shorter hospital stay, 
are obvious. Additionally, endoscopic resection most often 
leads to curative en bloc resection, which is mandatory and 
must be specifically considered as a quality measure.
The question that needs to be answered is whether 
endoscopic treatment offers an equal or higher quality of 
oncologic therapy for early colorectal cancer than surgery. 
Considering the fact that endoscopic treatment is usually 
less invasive than surgery and bearing in mind the afore-
mentioned advantages, can we then rightfully imply that 
endoscopic treatment is not just a competitor or an alter-
native to surgery but should be the method of choice in 
the care of selected patients with early colorectal cancer?
In this paper, various aspects of endoscopic treat-
ment of early colorectal cancer will be highlighted and the 
progress that has been made in the past decade will be 
demonstrated. The pros and cons of endoscopic therapy 
as opposed to surgery will be discussed. At the end of this 
argumentative paper, it should become evident that, in 
certain situations, endoscopic therapy is the method of 
choice and not just a competition with surgery.
Early colorectal cancer
Early colorectal cancer with a submucosal invasion depth 
of ≤1000 μm and without lymphovascular/vascular inva-
sion or tumor budding is traditionally considered as a low-
risk cancer with a risk of lymph node (LN) metastasis of 
<1% [1]. In a systematic review and meta-analysis of histo-
pathologic factors influencing the risk of LN metastasis in 
early colorectal cancer, Beaton et al. [2] analyzed 23 cohort 
studies including >4000 patients and could demonstrate 
that in early colorectal cancer a depth of submucosal inva-
sion by the tumor of >1  mm, lymphovascular invasion, 
poor differentiation, and tumor budding are significantly 
associated with LN metastasis. Various studies have shown 
that the quality of evidence regarding pathologic predic-
tive factors is poor, and in select patients, endoscopic 
resection alone may be adequate even in the presence of 
deep submucosal invasion of >1000 μm [3]. However, the 
depth of submucosal invasion may often be subjective and 
not always reproducible between pathologists.
For tumor budding, there is now a recently accepted 
international consensus system for the reporting, scoring, 
and assessment of tumor budding in colorectal cancer 
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[4]. Tumor budding is an independent predictor of LN 
metastasis in pT1 colorectal cancer [5, 6], and this scoring 
system should be part of the pathologic workup of early 
colorectal cancers.
In addition to these traditional predictive markers of 
clinical outcome in colorectal cancer, the routine testing 
for molecular biomarkers, including mismatch repair 
(MMR) deficiency and microsatellite instability (MSI), is 
now recommended because it offers additional molecular 
biological information for the risk stratification of colo-
rectal cancers [7]. Poor differentiation or undifferentiated 
cancers, for example, are usually considered high risk, 
although poor differentiation in the context of MMR defi-
ciency/MSI is considered low risk. Abundant evidence 
suggests that MMR status is a valuable prognostic and 
predictive biomarker for nonmetastatic colorectal cancer 
and so should be performed routinely [8].
Guidelines
The European Society of Gastrointestinal Endoscopy 
(ESGE) recommends ESD for the en bloc resection of colo-
rectal lesions with a high suspicion of limited submucosal 
invasion, especially for lesions larger than 20 mm. In these 
guidelines, the endoscopic suspicion of submucosal inva-
sion is based on two main features: (1) an irregular surface 
pattern or a nongranular laterally spreading tumor (LST) 
type and (2) a depressed or pseudodepressed morphol-
ogy (Figure 1) [9]. LST nongranular-type lesions have 
been shown to have a relatively high risk for submucosal 
invasive cancer of up to 69%, and in lesions with a pseu-
dodepressed morphology, this risk rises even up to 73.5% 
[10]. Other data show a risk of multifocal submucosal 
invasion in approximately 30–56% of all nongranular 
colorectal lesions [11]. As such, great emphasis must be 
laid on the en bloc resection of such lesions to make a reli-
able histopathologic analysis of tumor margins possible.
Endoscopic resection techniques
Endoscopic mucosal resection (EMR)
EMR is performed using a snare and usually after the sub-
mucosal lifting of the lesion by fluid injection. Snares of 
different sizes and braiding can be used depending on the 
size and morphology of the lesion. EMR is usually indi-
cated for benign adenomas and smaller lesions (<20 mm). 
In these lesions, an en bloc resection rate of up to 80% 
can be achieved [12, 13]. However, with flat lesions exceed-
ing a particular size, EMR often results in a “piecemeal” 
strategy that has a relatively high risk of recurrence [14]. In 
one study on 479 patients, the risk of recurrence after EMR 
was up to 41% in lesions >40 mm in size [15]. In another 
study on 252 large nonpedunculated adenomas (>20 mm), 
evident residual neoplasia was seen in 31.69% of lesions 
followed up after 3–6 months [16].
For large colorectal polyps, underwater EMR (UEMR) 
was recently directly compared to conventional EMR with 
regard to efficacy and safety [17]. UEMR was associated 
with fewer recurrences and earlier curative resections 
compared to conventional EMR with no significant differ-
ence in adverse events rate.
LST with a uniformly granular surface morphology 
have a low risk of submucosal invasive cancer, so piece-
meal EMR is considered sufficient as an endoscopic treat-
ment modality (Figure 2A–C) [18]. Colorectal lesions with 
a Paris type Ip morphology are also excellently well suited 
for snare resection, and even large pedunculated polyps 
with cancerous differentiation can be resected in toto, 
provided the snare is positioned correctly at the base of 
the stalk (Figure 3A and B).
In early colorectal cancer, an R0 resection of the lesion 
is paramount. As the histopathologic analysis of the resec-
tion margins is not possible after piecemeal resection, 
all lesions with a high suspicion of invasive cancer, as 
described above, must undergo a treatment modality with 
a good chance of en bloc resection. In this situation, EMR 
has its limitations and other methods such as the ESD are 
preferable [19].Figure 1: LST nongranular type with a depressed surface.
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ESD
ESD has significantly better clinical outcomes than EMR 
with low recurrence rates of about 1.2% [20]. In a current 
meta-analysis by Fuccio et al. [21], ESD for colorectal neo-
plasia was reported to have excellent en bloc resection 
rates of 86% in non-Asian countries and up to 93% in Asia. 
Although the curative R0 resection rates differed signifi-
cantly between Asian (86%) and non-Asian (73%) coun-
tries, further progress is constantly being made even in 
European countries. For example, Probst et al. [10] recently 
demonstrated an R0 resection rate of up to 84% for benign 
colorectal neoplasias and a low recurrence rate of <5%.
ESD involves the circumferential mucosal incision 
around the lesion or tumor and subsequently the step-
wise dissection of the submucosa underneath the tumor 
and just above the proper muscle layer (Figure 4A–D). 
Special knives are used depending on the preference of 
the endoscopist. Recently, ESD knives with the ability of 
both injection and dissection have been developed, ena-
bling easy and quick manipulation without the change of 
instruments.
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Figure 2: (A–C) Piecemeal EMR of an LST granular type in the cecum.
Figure 3: (A and B) Snare EMR of a small pedunculated carcinoma.
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ESD in general is a “difficult to learn” procedure and 
requires a high level of practice and dedication to achieve 
a satisfactory level of proficiency [22]. ESD in the right 
hemicolon probably belongs to the most difficult and 
tedious endoscopic resection procedures. In a prospective 
single-center series on 182 cases localized mostly proxi-
mal to the rectum, en bloc and R0 resection rates of 88.4% 
and 62.6%, respectively, were reported [23]. Furthermore, 
the efficacy of ESD for lesions up to 50  mm was shown 
to be satisfactory, whereas larger lesions were associated 
with low R0 resection rates and long procedure times. 
For lesions between 20 and 50  mm, a mean procedure 
time of 92.7  min was recorded. This single-center report 
underlines the fact that ESD is feasible and efficient even 
in the right hemicolon. However, it also shows that large 
colonic lesions proximal to the rectum still pose a major 
challenge to western endoscopists, and for large colonic 
lesions with suspected submucosal invasion, an alterna-
tive approach is warranted. It is obvious that ESD in the 
colon is technically challenging and time-consuming; 
however, in the hands of an expert, it becomes an impor-
tant “first-choice option” for the treatment of early colo-
rectal cancer. Although the colon ESD perforation rate 
in the study of Sauer et  al. [23] was about 9%–10%, the 
rate of perforations leading up to emergency surgery was 
low (just about 1%) and most perforations were treated 
endoscopically.
Endoscopic full-thickness resection (EFTR)
The endoscopic treatment of neoplasms in the GI tract 
experienced a major breakthrough with the introduction 
of the EFTR technique. In their review paper, Schmidt 
et  al. [24] described classical indications for EFTR and 
include the “re-resection” of T1 carcinomas, the curative 
treatment of early colorectal lesions, and the resection 
of polyps in difficult anatomic localizations. When an 
early colorectal cancer is wrongly diagnosed as a benign 
adenoma and then resected classically using piecemeal 
EMR, it may become impossible to determine the R-status 
or the depth of submucosal invasion. In this situation, 
EFTR becomes a valuable instrument to obtain a full-
thickness specimen of the resection site, broadening the 
diagnostic repertoire.
In the case of a correctly diagnosed early colorectal 
cancer, EFTR leads to a complete (R0) resection of the 
neoplasm including the underlying muscularis propria 
A
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Figure 4: (A and B) ESD resection of an early carcinoma in the transverse colon and (C and D) ESD resection of a rectum adenoma with high-
grade intraepithelial neoplasia (HGIEN).
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as well as the immediate closure of the resulting defect 
(Figure 5A–C). An accurate histologic diagnosis of the 
depth of submucosal invasion is possible.
The FTRD® (“Full Thickness Resection Device”; 
Ovesco, Tuebingen, Germany) is the over-the-scope device 
that has been approved for EFTR in the lower GI tract in 
Europe since September 2014.
The minimally invasive surgical methods for a full-
thickness resection of an early rectal cancer include 
transanal endoscopic microsurgery (TEMS) and transanal 
minimally invasive surgery (TAMIS), and like the EFTR, 
they usually lead to full-thickness resection specimens of 
rectal lesions. Whereas these transanal surgical methods 
are limited to the rectum, the EFTR using the FTRD® can 
be implemented in all sections of the colorectum, includ-
ing the cecum.
Furthermore, EFTR using the FTRD® offers an impor-
tant option for the endoscopic treatment of difficult lesions 
that when treated with EMR or ESD may result in the per-
foration of the colon. Such lesions include polyps with 
the “nonlifting sign” due to scarring, recurrent lesions, or 
lesions with submucosal infiltration. Neoplasms arising 
in the appendiceal orifice or in close proximity to diver-
ticula have also been shown to be resectable with EFTR.
In a recently published prospective multicenter study 
on 181 patients in nine centers, EFTR using the FTRD® 
was technically successful in 89.5% with an R0 resection 
rate of 76.9%, and in cases with cancer, R0 resection was 
achieved in 72.4%. EFTR was shown to be safe with a 2.2% 
rate of emergency surgery due to complications [25].
Endoscopy or surgery?
The endoscopic treatment of early colorectal cancer is 
effective and minimally invasive and has a low recurrence 
rate, and it can be rightfully postulated that endoscopy 
has overtaken surgery in many cases of early colorectal 
cancer.
Although direct comparative studies between ESD 
and surgery are lacking, a retrospective comparison 
of both methods for early colorectal cancer indicated a 
better quality of life for patients after ESD [26]. Even the 
resection of rectal cancers that have encroached into the 
upper anal canal as well as tumors in the colon can be 
successfully resected endoscopically using ESD or EFTR, 
respectively.
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Figure 5: (A–C) EFTR of a T1 carcinoma in the descending colon.
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TEMS and TAMIS are excellent surgical treatment 
options for early rectal cancer. These procedures remain 
more invasive than ESD or EFTR, and some studies have 
even shown significantly higher recurrence rates [27, 28]. 
However, as the case in most complex resection proce-
dures, the quality of local endoscopic resection surgery 
and the steep learning curve plays an important role in 
the risk of recurrence [29].
Bach et al. [30] described a predictive model for local 
recurrence after TEMS for rectal cancer and found that 
three histopathologic variables were independent predic-
tors of local recurrence: the depth of tumor invasion, the 
presence of lymphovascular invasion, and the maximum 
tumor diameter.
The management of unfavorable histopathologic 
findings after the local excision of colorectal cancers 
often includes a radical surgical resection. Several 
studies have reported that the oncologic outcomes in 
patients treated by immediate radical surgery after local 
excision for unfavorable histologic findings are compa-
rable to that of radical surgery performed as a primary 
treatment [31]. However, a careful endoscopic assess-
ment of colorectal lesion using various endoscopic clas-
sifications, chromoendoscopy, as well as magnification 
endoscopy should be done before the choice of treat-
ment is made. The correct pretherapeutic evaluation of 
such lesions may help to distinguish between precancer-
ous adenomas and deeply invasive cancer and as such 
improves the choice of therapeutic approach. It may be 
helpful to mark lesions not eligible for endoscopic resec-
tion with a submucosal tattoo to facilitate the locali-
zation of the resection site during surgery, especially 
when a laparoscopic-assisted resection is performed 
subsequently.
Complications after the TAMIS procedure are infre-
quent with an overall rate of 7.4%, and in TEMS, the 
most common complications include hemorrhage (27%), 
urinary tract infection (21%), and suture line dehiscence 
(14%) [31]. The adverse effects of full resectional surgery 
are well documented with a total mortality rate of 3.3%, 
clinical leak rates of 16% if a diverting stoma was not used, 
interruption of autonomic innervation to the bladder and 
sexual organs, urinary incontinence in 34%, and fecal 
incontinence in up to 60% of patients [31]. The early detec-
tion of rectal cancers through screening programs should 
increase the chances of treating more colorectal cancers in 
an early stage using local resection techniques with much 
lower morbidity and mortality rates [30].
As a result of these significant differences in the 
adverse effect rates between full resectional surgery and 
local resection, patients’ attitudes will tend toward local 
resections techniques, especially if explained carefully by 
an expert with experience in the procedure.
The indications for TAMIS are similar to TEMS and 
include benign rectal neoplasms or well-selected T1 
cancers with histologically favorable features where the 
risk of nodal metastasis is low [32]. In unclear situations, 
with questionable T1 versus T2 morphology with no evi-
dence of nodal metastasis, a TAMIS resection can serve as 
an “excisional biopsy,” guiding further treatment with the 
final pathology report [32]. A more radical oncologic resec-
tion may then be implemented if the pathology returns 
as a T2 lesion [32]. Finally, patients with more advanced 
lesion (T3) who are medically unfit to have a more radical 
surgery can be considered for TAMIS resection [32].
In the management of early colorectal cancer, a mul-
tidisciplinary discussion between the endoscopist and the 
rectal surgeon is often necessary to ensure the optimal 
choice of treatment for the patient.
After the curative local resection of early colorectal 
cancer, endoscopic follow-up is necessary with a colonos-
copy at 1 year and thereafter depending on the findings. 
For rectal cancer, a proctoscopy every 6 months for 5 years 
is generally recommended [31].
Conclusion
We can rightfully conclude that the endoscopic treatment 
of early colorectal cancer is not just a competition with 
surgery but should be, with some exceptions, the treat-
ment of choice for low-risk colorectal lesions. A surgical 
approach is warranted in certain situations especially 
where endoscopic treatment fails or in the presence of 
high-risk features. The management of early colorec-
tal cancers using local excision methods such as ESD or 
EFTR and TEMS or TAMIS in the rectum has significantly 
improved morbidity and mortality associated with cancer 
resection while at the same time maintaining excellent 
clinical and oncologic outcomes. Finally, as colorectal 
cancer screening programs have led to an increase in the 
detection of early-stage colorectal cancer, physicians, 
health-care providers, surgeons, and gastroenterologists 
must be educated on the possibilities, strengths, and pit-
falls of these methods and ensure that their patients are 
informed and guided adequately.
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Comments to Authors:
Endoscopic treatment of early colorectal cancer - just a competition with surgery? 
 
This manuscript highlights various aspects of the endoscopic treatment of colorectal cancer when compared to full resectional surgery. 
 
I have the following comments and suggestions that the authors may wish to consider: 
 
Major comments: 
1) Low risk pT1 cancers include both well and moderately differentiated adenocarcinomas. Most are moderately differentiated rather than 
well differentiated, Poor differentiation or undifferentiated cancers are usually considered high risk, although poor differentiation in the 
context of mismatch repair deficiency/microsatellite instability is considered low risk. TNM version 8 now recommends routine testing 
of MMR status in all colorectal cancers so molecular biological information should now be routinely available in addition to traditional 
morphological classifiers of risk. This should be acknowledged. 
2) Features of high and low risk pT1s are presented as either one or the other, but unfortunately even what appear to be objective 
measurements e.g. depth of submucosal invasion, are subjective and are not proven to be reproducible between pathologists. This 
subjectivity when assessing risk should be acknowledged. 
3) Budding is presented as a high risk feature, yet there are several systems which are subjective and confusing. There is now a recently 
accepted international consensus system for analysing budding. This should be referenced. 
4) The authors state “However, other studies have shown that the quality of evidence regarding these pathologic predictive factors is poor 
and in select patients endoscopic resection alone may be adequate even in the presence of submucosal invasion (3).” It is not clear how 
this statement relates to the previous sentence, which highlights high risk features predicting nodal metastases. Submucosal invasion 
alone is not a high risk feature, it is the definition of a cancer rather than a pre-cancerous adenoma with high grade dysplasia. 
5) Please clarify whether EFTR includes locally excised surgical specimens such as TEMS or TAMIS? If not please clarify for the reader how 
these procedures differ in terms of the specimen produced. 
6) Similar to the quality of mesorectal surgery predicting outcomes, it is likely that the quality of local excision surgery is also related to the 
risk of recurrence. Positive margins can be seen if the tumour is understaged, or if there is a failure to stick to the intended tissue planes, 
especially at the lateral edges of the local excision where there is a tendency to ‘cone in’, A comment on the importance of the quality of 
local excision surgery would be helpful. 
7) Br J Surg. 2009; 96: 280-90 describes the risk of recurrence according to various high risk features. It is surprising that this important 
study is not referenced in the review. 
8) The review suggests that early cancers should now be resected using local excision. The review does not really expand on the issue 
raised in the title i.e. how the use of local excision vs. surgery is being used for these lesions around the world. How many lesions are 
inappropriately being offered surgery at the current time in different healthcare systems? How do we change this to ensure that more are 
locally resected, if appropriate? A summary flow chart of the questions that should be asked when deciding between local excision and full 
surgery would be helpful. 
9) Other points of interest are not sufficiently addressed. The relative morbidity and mortality of local techniques and full resectional 
surgery should be presented. How intensively should patients be followed up following local excision of an early cancer? How does full 
resection after local recurrence following local excision affect long term outcomes compared to primary resectional surgery? What are 
patient attitudes to local excision vs. full resectional surgery? 
 
Minor comments: 
1) “proper muscle layer” is better clarified as the muscularis propria. 
2) I am not sure how much the endoscopic images used as figures help the reader to make a decision about the use of an endoscopic 
procedure vs. surgery.
Reviewer 2: Eloy Espi
Sep 17, 2017
Reviewer Recommendation Term: Revise with Major Modification
Overall Reviewer Manuscript Rating: N/A
Custom Review Questions Response
Is the subject area appropriate for you? 4
Does the title clearly reflect the paper’s content? 5 - High/Yes
Does the abstract clearly reflect the paper’s content? 4
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Do the keywords clearly reflect the paper’s content? 4
Does the introduction present the problem clearly? 4
Are the results/conclusions justified? 4
How comprehensive and up-to-date is the subject matter presented? 5 - High/Yes
How adequate is the data presentation? 5 - High/Yes
Are units and terminology used correctly? 4
Is the number of cases adequate? N/A
Are the experimental methods/clinical studies adequate? N/A
Is the length appropriate in relation to the content? 4
Does the reader get new insights from the article? 2
Please rate the practical significance. 2
Please rate the accuracy of methods. N/A
Please rate the statistical evaluation and quality control. N/A
Please rate the appropriateness of the figures and tables. 4
Please rate the appropriateness of the references. 4
Please evaluate the writing style and use of language. 4
Please judge the overall scientific quality of the manuscript. 3
Are you willing to review the revision of this manuscript? Yes 
Comments to Authors:
I had the privilege of reviewing this paper, a review of the evidence on endoscopic treatment of early colorectal cancer. 
I think is a good review in terms of easy reading and good figures.  
I have some advices: 
1.- In abstract change: “.... the methods of choice for the treatmentof early colorectal cancer....” for “the methods of choice for the treatment 
of most early colon cancer and some rectal cancer...” 
2.- In introduction...change “should be the method of choice in the care of patients with early colorectal cancer?” to “should be the method 
of choice in the care of selected patients with early colorectal cancer?” 
3.- In the section of endoscopy vs surgery... It should be a better explanation of the cases where surgery should be preferred to endoscopy. 
4.- In rectal cancer there has been a good experience with TEM and TAMIS surgery (not even mentioned). There are good results with these 
approach. In the same section I think that is important to mark the importance of the complete study of all malignant lesions BEFORE the 
resection, in order to a good clinical decision of resection vs other kind of treatment (studying the patient after the resection is linked to 
conflicts in the decision making process). 
5.- I think is important to give some words to the importance of tatooing the lesions to a better control after the resection (re-endoscopy, 
surgery, etc).
Authors’ Response to Reviewer Comments
Oct 04, 2017
Dear Editors and reviewers,  
 
Please find attached, a point-by-point revision of our manuscript “Endoscopic treatment of early colorectal cancer – just a competition with 
surgery?”  
The authors wish to thank the reviewers for their detailed comments and hope the revised manuscript now qualifies for publication.  
Best regards  
 
Reviewers’ comments:  
 
Reviewer #1: Endoscopic treatment of early colorectal cancer - just a competition with surgery?  
This manuscript highlights various aspects of the endoscopic treatment of colorectal cancer when compared to full resectional surgery.  
I have the following comments and suggestions that the authors may wish to consider:  
 
Major comments:  
IV      Ebigbo et al.: Endoscopic treatment of early colorectal cancer
1) Low risk pT1 cancers include both well and moderately differentiated adenocarcinomas. Most are moderately differentiated rather than 
well differentiated, Poor differentiation or undifferentiated cancers are usually considered high risk, although poor differentiation in the 
context of mismatch repair deficiency/microsatellite instability is considered low risk. TNM version 8 now recommends routine testing of 
MMR status in all colorectal cancers so molecular biological information should now be routinely available in addition to traditional morpho-
logical classifiers of risk. This should be acknowledged.  
>> Acknowledged  
2) Features of high and low risk pT1s are presented as either one or the other, but unfortunately even what appear to be objective measure-
ments e.g. depth of submucosal invasion, are subjective and are not proven to be reproducible between pathologists. This subjectivity when 
assessing risk should be acknowledged.  
>> Acknowledged  
3) Budding is presented as a high risk feature, yet there are several systems which are subjective and confusing. There is now a recently 
accepted international consensus system for analysing budding. This should be referenced.  
>> Referenced  
4) The authors state “However, other studies have shown that the quality of evidence regarding these pathologic predictive factors is poor 
and in select patients endoscopic resection alone may be adequate even in the presence of submucosal invasion (3).” It is not clear how this 
statement relates to the previous sentence, which highlights high risk features predicting nodal metastases.  
>> The statement tries to justify the endoscopic resection of early rectal cancer even in the presence of high risk features bearing in mind 
that the quality of evidence regarding these features is poor.  
Submucosal invasion alone is not a high risk feature, it is the definition of a cancer rather than a pre-cancerous adenoma with high grade 
dysplasia.  
>> We meant “deep” sm-invasion, we have changed this in the text.  
5) Please clarify whether EFTR includes locally excised surgical specimens such as TEMS or TAMIS? If not please clarify for the reader how 
these procedures differ in terms of the specimen produced.  
>> Clarified  
6) Similar to the quality of mesorectal surgery predicting outcomes, it is likely that the quality of local excision surgery is also related to the 
risk of recurrence. Positive margins can be seen if the tumour is understaged, or if there is a failure to stick to the intended tissue planes, 
especially at the lateral edges of the local excision where there is a tendency to ‘cone in’, A comment on the importance of the quality of 
local excision surgery would be helpful.  
>> A comment has been included.  
7) Br J Surg. 2009; 96: 280-90 describes the risk of recurrence according to various high risk features. It is surprising that this important 
study is not referenced in the review.  
>> Referenced  
8) The review suggests that early cancers should now be resected using local excision. The review does not really expand on the issue raised 
in the title i.e. how the use of local excision vs. surgery is being used for these lesions around the world. How many lesions are inappro-
priately being offered surgery at the current time in different healthcare systems? How do we change this to ensure that more are locally 
resected, if appropriate? A summary flow chart of the questions that should be asked when deciding between local excision and full surgery 
would be helpful.  
>> Due to the heterogeneity of the lesions and their localisations involved in this topic and the different levels of expertise in various parts of 
the world, the authors do not think that a simple summary flow chart can render sufficient justice to the question of therapeutic approach. 
However, we have stated that lesions should generally be evaluated extensively by an expert experienced in the endoscopic evaluation and 
treatment of colorectal lesions, and in many situations, a multidisciplinary discussion between endoscopist and rectal surgeon becomes 
necessary to ensure appropriate treatment.  
9) Other points of interest are not sufficiently addressed. The relative morbidity and mortality of local techniques and full resectional sur-
gery should be presented. How intensively should patients be followed up following local excision of an early cancer? How does full resec-
tion after local recurrence following local excision affect long term outcomes compared to primary resectional surgery? What are patient 
attitudes to local excision vs. full resectional surgery?  
>> The authors have included these aspects.  
 
Minor comments:  
1) “proper muscle layer” is better clarified as the muscularis propria.  
>> Clarified  
Ebigbo et al.: Endoscopic treatment of early colorectal cancer      V
2) I am not sure how much the endoscopic images used as figures help the reader to make a decision about the use of an endoscopic proce-
dure vs. surgery.  
>> The authors included the images to illustrate the endoscopic treatment options available for the treatment of early colorectal cancer. Also 
reviewer 2 has commented these images as “good figures”.  
 
Reviewer #2: I haga had the privilege of reviewing this paper, a review of the evidence on endoscopic treatment of early colorectal cancer.  
I think is a good review in terms of easy reading and good figures.  
I have some advices:  
1.- In abstract change: “.... the methods of choice for the treatmentof early colorectal cancer....” for “the methods of choice for the treatment 
of most early colon cancer and some rectal cancer...”  
>> Changed  
2.- In introduction...change “should be the method of choice in the care of patients with early colorectal cancer?” to “should be the method 
of choice in the care of selected patients  
with early colorectal cancer?”  
>> Changed  
3.- In the section of endoscopy vs surgery... It should be a better explanation of the cases where surgery should be preferred to endoscopy.  
>> The authors have now included this.  
4.- In rectal cancer there has been a good experience with TEM and TAMIS surgery (not even mentioned). There are good results with these 
approach. In the same section I think that is important to mark the importance of the complete study of all malignant lesions BEFORE the 
resection, in order to a good clinical decision of resection vs other kind of treatment (studying the patient after the resection is linked to 
conflicts in the decision making process).  
>> Included with detailed emphasis on TAMIS.  
5.- I think is important to give some words to the importance of tatooing the lesions to a better control after the resection (re-endoscopy, 
surgery, etc).  
>> Done
Reviewers’ Comments to Revision 
Reviewer 1: anonymous
Oct 09, 2017
Reviewer Recommendation Term: Accept
Overall Reviewer Manuscript Rating: 75
Custom Review Questions Response
Is the subject area appropriate for you? 4
Does the title clearly reflect the paper’s content? 4
Does the abstract clearly reflect the paper’s content? 4
Do the keywords clearly reflect the paper’s content? 4
Does the introduction present the problem clearly? 4
Are the results/conclusions justified? 4
How comprehensive and up-to-date is the subject matter presented? 5 - High/Yes
How adequate is the data presentation? N/A
Are units and terminology used correctly? 5 - High/Yes
Is the number of cases adequate? N/A
Are the experimental methods/clinical studies adequate? N/A
Is the length appropriate in relation to the content? 4
Does the reader get new insights from the article? 4
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Please rate the practical significance. 4
Please rate the accuracy of methods. N/A
Please rate the statistical evaluation and quality control. N/A
Please rate the appropriateness of the figures and tables. 3
Please rate the appropriateness of the references. 5 - High/Yes
Please evaluate the writing style and use of language. 4
Please judge the overall scientific quality of the manuscript. 4
Are you willing to review the revision of this manuscript? Yes 
Comments to Authors:
The authors have addressed all of my comments satisfactorily. I have no further issues to raise.
Reviewer 2: Eloy Espi
Oct 07, 2017
Reviewer Recommendation Term: Accept
Overall Reviewer Manuscript Rating: 70
Custom Review Questions Response
Is the subject area appropriate for you? 4
Does the title clearly reflect the paper’s content? 4
Does the abstract clearly reflect the paper’s content? 4
Do the keywords clearly reflect the paper’s content? 4
Does the introduction present the problem clearly? 4
Are the results/conclusions justified? 4
How comprehensive and up-to-date is the subject matter presented? 4
How adequate is the data presentation? 5 - High/Yes
Are units and terminology used correctly? 5 - High/Yes
Is the number of cases adequate? N/A
Are the experimental methods/clinical studies adequate? 4
Is the length appropriate in relation to the content? 4
Does the reader get new insights from the article? 3
Please rate the practical significance. 3
Please rate the accuracy of methods. 4
Please rate the statistical evaluation and quality control. N/A
Please rate the appropriateness of the figures and tables. 4
Please rate the appropriateness of the references. 4
Please evaluate the writing style and use of language. 4
Please judge the overall scientific quality of the manuscript. 3
Are you willing to review the revision of this manuscript? Yes 
Comments to Authors:
-
